Formularies represent the fundamental approach embodied in the World Health Organization (WHO) Model Formulary 2004 and various countries' essential medicines lists. Limitations include its generalizability to all types of formulary committees and settings, and lack of time and data for committees to fully address all checklist questions.ĭrug formularies are a ubiquitous, heterogeneous yet often contentious feature of both US and international drug policy –.It can educate new committee members, guide discussions of drugs proposed for formulary addition, and be used to evaluate the quality of committee decision making. The checklist can facilitate more standardized and critical scrutiny of the evidence and therapeutic alternatives.The tool poses 48 questions related to: evidence of need, efficacy, medication safety, misuse potential, cost issues, and decision-making process.We developed a tool based on a project at two US public academic hospitals consisting of a six-domain checklist of questions for evaluating drugs requested for addition.Although considerable attention has been devoted to their role in cost containment, formularies' role in guiding rational drug use remains underdeveloped and could be enhanced by a more standardized critical evaluation of drugs proposed for formulary placement. Drug formularies are widely used by hospitals, health systems, and private and national drug insurance plans.Provenance: Not commissioned externally peer reviewed. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. Grants received: Abbott (readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). (my own company, specializing in preventing and detecting drug name confusion errors). BL consulted in last 3 years: Abbott (drug name confusion), Transcept. DT received unrestricted grant funding for research from Medco Health Solutions. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc, Rockville, MD. SW consulted for Abbott, Genentech, Primus. JD had a summer student internship with Abbott Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with Walgreens (member of P&T Committee, ∼$5,000). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.įunding: This work originated from the Formulary Leveraged Improved Prescribing (FLIP) project, which was funded by the Attorney General Consumer and Prescriber Education Grant Program, and was supported by the Agency for Healthcare Research and Quality grant U18HS016973 funding the UIC Center for Education and Research on Therapeutics (CERT) program. PLoS Med 9(5):Ĭopyright: © 2012 Schiff et al. (2012) A Prescription for Improving Drug Formulary Decision Making. Citation: Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, Pontikes P, et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |